Cancer Advisor

OneDayMD  |  Integrative Oncology Review ISSN (Online) pending  •  Volume 1, Issue 1  •  Published: 10 August 2025  •  Updated: 15 June 2026 Case Series & Mechanistic Review Compiled tumour marker responses, radiologic outcomes, and mechanisms of anti-cancer action across an international patient cohort Last updated: 15 June 2026 DOI: pending  •  Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Stage 4 PDAC: A Compiled Case Series of 28 Patients. OneDayMD Integr Oncol Rev. 2025;1(1). Updated June 2026. Evidence Classification All case reports in this series represent CEBM Level 4–5 evidence (case reports and expert opinion). This compilation is hypothesis-generating. No randomised controlled trials of ivermectin, fenbendazole, or mebendazole for pancreati...

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers worldwide. With a 5-year survival rate of only 13% (American Cancer Society, 2026 data) and dropping to 3% for metastatic disease, PDAC has seen little improvement in outcomes over the past decades. Late diagnosis, dense tumor stroma, and near-universal KRAS mutations (90-95% of cases) drive rapid resistance to standard chemotherapy. Most patients are diagnosed at advanced stages, and resistance to chemotherapy develops rapidly. However, 2025–2026 has brought an unprecedented wave of breakthroughs that may finally shift the landscape of pancreatic cancer treatment.  A landmark triple drug therapy for pancreatic cancer, detailed in a December 2025/January 2026 study published in  Proceedings of the National Academy of Sciences  (PNAS) by researchers at Spain’s National Cancer Research Centre (CNIO), has delivered unprecedented preclinical results: complete tumor eradication in multiple...